The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin (BMRN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

The South San Francisco biotech has acquired rights to tralesinidase alfa, an enzyme replacement therapy (ERT) for the ...

Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended March 2025. While this widely-known consensus ...

BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BioMarin Pharmaceutical Inc.’s BMRN share price has dipped by 10.70%, which has investors questioning if this is right time to buy.

From Washington to Wall Street, it's a crazy time for biotech. But as Ultragenyx Pharmaceutical Inc. celebrates its 15th ...